Nanjing Aoluo Biotechnology

Nanjing Aoluo Biotechnology is a clinical-stage biotechnology company specializing in the development of mRNA-based vaccines and therapeutics for oncology and infectious diseases. Established in 2020 as a joint venture between Grand Pharmaceutical and eTheRNA Immunotherapies, the company utilizes the proprietary TriMix mRNA technology and lipid nanoparticle (LNP) delivery systems. Its lead candidate, A-002, is an mRNA-based immunotherapy targeting HPV16-positive solid tumors, specifically head and neck cancers. The company is establishing an integrated mRNA R&D and manufacturing facility in the Nanjing Jiangbei New District to support its pipeline and future commercialization efforts.